Physician profile
Steven Blumenthal
NPI 1568441921
$12,352.92
in general payments reported to CMS, 2019-2025
29 companies · $890 in 2025
The $890 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,284 · 2020: $2,520 · 2021: $1,240 · 2022: $1,097 · 2023: $740 · 2024: $583 · 2025: $890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,212.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardinal Health 110 LLC | $6,500.00 | 2019-2022 | |
| Amgen INC. | $1,183.08 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $730.88 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $697.97 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $692.47 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $416.65 | 2019-2025 | Farxiga, Wainua |
| Merck Sharp & Dohme LLC | $319.58 | 2021-2025 | Verquvo, Capvaxive |
| Regeneron Healthcare Solutions, INC. | $215.40 | 2019-2024 | Evkeeza |
| Medicomp INC | $184.50 | 2022-2025 | Telepatch Cardiac Monitor |
| Arbor Pharmaceuticals, INC. | $174.39 | 2019-2021 | |
| Pfizer INC. | $153.36 | 2019-2025 | |
| Abbott Laboratories | $150.06 | 2019-2025 | Aveir |
| Amarin Pharma, INC. | $145.11 | 2019 | |
| Boston Scientific Corporation | $134.77 | 2019-2023 | Rotapro |
| Biotronik INC. | $99.98 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $67.73 | 2020-2024 | Livalo |
| Bardy Diagnostics, INC. | $65.82 | 2022 | |
| Tanabe Pharma America, INC. | $55.27 | 2023-2024 | |
| Novo Nordisk INC | $50.93 | 2024-2025 | Ozempic, Rybelsus |
| Lexicon Pharmaceuticals, INC. | $44.69 | 2023-2024 | Inpefa |
| Cvrx, INC. | $42.79 | 2025 | Barostim Neo System |
| Lundbeck LLC | $42.60 | 2019 | |
| Bridgebio Pharma, INC. | $42.42 | 2025 | Attruby |
| Lilly USA, LLC | $30.48 | 2024 | Zepbound |
| Allergan, INC. | $24.98 | 2019 | |
| Glaxosmithkline, LLC. | $24.48 | 2025 | Arexvy, Shingrix |
| Inspire Medical Systems, INC. | $24.47 | 2024 | Inspire |
| Sanofi-Aventis U.S. LLC | $22.50 | 2021 | |
| Heartflow, INC. | $15.56 | 2023 | Ffrct |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Blumenthal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.